Total medical devices industry deals worth $7.09bn were announced globally for March 2021, with the $1.07bn asset transaction with Lumenis being the sector’s biggest investment, according to GlobalData’s deals database.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 60.4% over the previous month of $4.42bn and a drop of 27.6% when compared with the last 12-month average of $9.79bn.
In terms of number of deals, the sector saw a drop of 4.82% with 158 deals in March 2021 when compared to the last 12-month average of 166 deals.
In value terms, North America led the activity with deals worth $4.89bn in March 2021.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMedical Devices industry deals in March 2021: Top deals
The top five deals accounted for 50.2% of the overall value during March 2021.
The combined value of the top five deals stood at $3.56bn, against the overall value of $7.09bn recorded for the month.
The top five medical devices industry deals of March 2021 tracked by GlobalData were:
1) Boston Scientific’s $1.07bn asset transaction with Lumenis
2) The $1bn private equity deal with Cardinal Health by Hellman & Friedman
3) Agilent Technologies’ $695m acquisition of Resolution Bioscience
4) The $475m acquisition deal of Northfield Medical by Agiliti
5) Bio Techne’s acquisition deal with Asuragen for $320m.
